Development Programs

infectious disease

Advancing the next phase of our immune-modulation platform programs

Themis has built a proven platform to effectively address the need for novel vaccines and to expand the potential of the platform to prevent large market infectious diseases and treat other indications like cancer. The most advanced development indications include Noro virus, RSV and CMV.


Norovirus is the most common cause of acute gastroenteritis in the United States alone. Each year, it causes 20 million cases of illness and contributes to multiple thousands of hospitalizations and several hundred deaths. Additionally, the Norovirus is also the most common cause of foodborne-disease outbreaks. The infection can be serious, especially for young children and older adults.


Respiratory syncytial virus (RSV) is the most common germ that can cause serious infections in infants, especially those in certain high-risk groups. Currently there is no vaccination against RSV available.


In the United States congenital cytomegalovirus infection is the most common viral infection of infants. About 1 in 150 children is born infected. The infection causes more long-term problems and childhood deaths than Down syndrome, fetal alcohol syndrome, and neural tube defects.


In 2016, the World Health Organization (WHO) declared the Zika virus a public health emergency of international concern Zika virus disease is caused by the Zika virus which is spread through the bite of infected mosquitoes. Outbreaks of Zika have been reported in tropical Africa, Southeast Asia, and the Pacific Islands. As there is currently no vaccine or preventive drug available, options to prevent Zika virus disease are limited.